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See related research by Wohlfarth et al., http://ccforum.com/content/18/1/R20We read with great interest the article by Wohlfarth and
colleagues [1] regarding the use of extracorporeal mem-
brane oxygenation (ECMO) in 14 adult patients with
hematological malignancies. We would like to highlight
two main points.
First, the authors focused their report and their discus-
sion on bleeding complications and anticoagulation man-
agement in this high-risk population. Although we concede
that it is a serious concern in these patients, it is not the
only one. ECMO support is associated with nosocomial
infections [2,3]. Impairment of cellular immunity, cytopenia
and chemotherapy (CT) may further increase the risks of
infection and may dissuade clinicians from using ECMO in
these patients. Developing new strategies that aim to limit
nosocomial infections is crucial to improving outcomes in
this population. ECMO in awake, non-intubated, spontan-* Correspondence: matthieuschmidt@yahoo.fr
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unless otherwise stated.eously breathing patients with acute respiratory distress
syndrome, to avoid mechanical ventilation and its related
adverse events, is a potentially promising application [4].
Thus, in our opinion, it would also be important to provide
a thorough description of nosocomial infections that might
have occurred in these 14 patients.
Second, the authors reported that 5 of 14 patients initially
received CT while receiving ECMO. The pharmacokinetics
of many of the medications administered to patients
receiving ECMO are complex [5] and, to date, there are
very limited data to guide our daily practice. Therefore,
clinicians must be aware that providing CT to patients
receiving ECMO is a potential gamble, which risks
worsening patient outcomes due to ineffective drug regi-
mens. CT during ECMO should be restricted to those
cases where postponing therapy is not an option.We thank the authors for their thoughtful considerations.
Eight of the ten cases of pneumonia leading to ECMO were
hospital-acquired. However, the number of proven
infections during the ICU stay was low. Of 110 cultures
(broncho-alveolar lavage, blood, urine, catheters, stool,
pleural/pericardial effusion, lung biopsies, wound swaps,
cerebrospinal fluid), only 6 were positive (catheter-related
infection, n = 5; urinary tract infection, n = 1). Reactivation
of cytomegalovirus or herpes simplex virus occurred in
one and three patients, respectively. All patients had
received broad-spectrum antibiotics, eight of them plus
antifungals.Even apart from ECMO, optimal timing, pharmacokinet-
ics and, therefore, dosing of CT in patients with acute
organ dysfunctions is largely unknown. Nevertheless, CT
may be the only option if hematologic malignancies
themselves cause organ dysfunction, especially in pulmon-
ary involvement [6]. Nowadays, administration of CT is
common practice in critically ill patients and affects every
fourth ICU patient with hematologic malignancies in dedi-
cated centers [7]. Importantly, CT does not negatively influ-
ence survival in large cohorts, even in cases of subsequent
sepsis [7-9]. By clinical judgment, postponing CT was not
an option in any of our five patients, of whom three are in
complete remission after 13, 15 and 46 months.
As a survival benefit of veno-venous ECMO still has
to be proven in patients with acute respiratory failure,
thorough case-by-case evaluation is absolutely essential.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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http://ccforum.com/content/18/5/522According to our findings, the risk of nosocomial infections
or CT-related issues should not lead to general exclusion
of patients with hematologic malignancies from ECMO.
Further research is warranted.
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